News Detail
Maryland, 23 Dec 2024: An FDA advisory panel vote of 9-1 to recommend the approval of Mesoblast Limited’s graft versus host disease (GVHD) cell therapy was a cruel tease for the Australian company.
More than four years later—and after two r......
View Details
Source : Fierce Pharma
Mesoblast
FDA approval
graft-versus-host disease
cell therapy
allogeneic cell therapy
Pharma
drugscontrol
Ryoncil
Related News
- Drug smuggler arrested with 160 Pentazocine in Faridabad (25-12-2024)
- Karnataka HC directs government not to act against firms producing nutraceuticals in drug-licensed units until next hearing (25-12-2024)
- DoP reprimands AbbVie Healthcare for unethical marketing practices (25-12-2024)
- 3 held with Rs 25 lakh regulated drugs in Mango Jamshedpur (25-12-2024)
- NCB Hyderabad dismantles an illicit Alprazolam unit in Telangana, 32.5 kg seized (25-12-2024)
- TSMC files 400 FIRs against quacks in Telangana (24-12-2024)
- District Collector issued instructions regarding Misused Banned Narcotic Drugs (24-12-2024)
- Dabur takes Patanjali to Delhi High Court over disparaging Chyawanprash ad (24-12-2024)
- PMO steps in, asks health ministry to act against misleading adverts (24-12-2024)
- AIIMS, Delhi developing low cost adaptive cellular therapy for treatment of multiple myeloma (24-12-2024)